|
|
Market
Size: The global Needle Free Injection Systems Market market was 4.5 billion USD in 2024 and is forecasted to achieve 10.2 billion USD by 2033, growing steadily at a CAGR of 9.8% from 2026 to 2033. The global pet diabetes care device market was $1.9 billion in 2021 and is projected to reach $3.5 billion by 2031. In the USA, the pet care diabetes drug industry was valued at US$ 621.8 million in 2022. By 2031, the market is expected to reach over US$ 1.1 billion.
Players: Antares Pharma (Halozyme Therapeutics), Endo International, Pharmajet, Bioject Medical Technologies, Medical International Technology, Injex Pharma, National Medical Products, Valeritas, European Pharma, Penject, Crossject.
Segments: The Needle Free Injection Systems Market is Segmented On The Basis Of Technology, Product Type, Application, End User, Technology, And Geography.
Regions: North America, Europe, Asia Pacific, and the Rest of the world.
Companies
1. PharmaJet: Leading supplier of needle-free injection equipment, PharmaJet has a solid track record of administering immunizations and prescription drugs. Their devices do not require needles because they use a spring-powered mechanism to precisely deliver medication through the skin. Over 20 million injections have been made using PharmaJet's technology globally, proving its dependability, effectiveness, and user-friendliness. PharmaJet is a privately held company, so there is no public stock price available for it, and its shares are not traded on stock exchanges. 2005 Year Founded, Status Private, 34 Employees, Latest Deal: Type 2ndary, Private Investors 24. https://pitchbook.com/profiles/company/57794-50. Golden, CO
2. Portal Instruments: When it comes to the advancement of needle-free jet injection technology, Portal Instruments is a pioneer. Their devices penetrate the skin and administer medication directly into the bloodstream through the use of a high-pressure liquid stream. The technology developed by Portal Instruments is especially well-suited for the delivery of large-molecule medications, including DNA-based therapeutics and proteins. Symbol: PORTAL https://finance.yahoo.com/quote/PORTAL29555-USD. Market Cap 25.343M. 2012 Year Founded, Status Private, 23 Employees, Latest Deal Type Series C Latest Deal Amount $42M, Investors 6. https://pitchbook.com/profiles/company/98048-62. Cambridge, MA
3. Medical International Technology (MIT): MIT is a top producer of needle-free injection tools for use in veterinary and human medicine. Their products are easy to use, safe, and efficient, which makes them perfect for use in a range of places, such as homes, clinics, and hospitals. The technology developed at MIT has been used to administer a variety of drugs, such as insulin, painkillers, and vaccines.Symbol: MDLH https://finance.yahoo.com/quote/MDLH. Montréal (Quebec) Canada. Market Cap (intraday) 185,470
4. NuGen Medical Devices: A Canadian business called NuGen Medical Devices designs and produces needle-free injection equipment for the administration of medications and vaccines. Their devices ensure full drug delivery by delivering medication through the skin and then withdrawing the fluid using a special bi-directional needle-free technology. The technology from NuGen is especially useful for administering sensitive or viscous drugs. Symbol: USA: NGMDF https://finance.yahoo.com/quote/NGMDF. Market Cap 9.059M. Canada: NGMD https://finance.yahoo.com/quote/NGMD.V. Market Cap 11.352M
5. Crossject SA: Swiss business Crossject SA creates and produces needle-free injection tools for subcutaneous and intramuscular injection administration. Their devices do not require needles because they use a spring-powered mechanism to precisely deliver medication through the skin. Over 10 million injections have been performed globally using Crossject's technology, proving its reliability, effectiveness, and user-friendliness. Symbol: ALCJ https://finance.yahoo.com/quote/ALCJ.PA. Market Cap (intraday) 77.563M
6. Bioject Medical Technologies: An American business called Bioject Medical Technologies designs and produces needle-free injection equipment for the administration of medications and vaccines. Their devices work by penetrating the skin with a high-pressure liquid stream to administer medication directly to the muscle or beneath the skin. Large-volume injection delivery is a particularly good fit for Bioject's technology. Symbol: BJCT https://www.investing.com/equities/bioject-medical-company-profile. Employees 33. As of December 5, 2016, Bioject Medical Technologies Inc. went out of business.
7. Enable Injections: An American business called Enable Injections designs and produces needle-free injection equipment for the administration of medications and vaccines. Their devices use a fine stream of fluid called microjet technology to deliver medication through the skin. The technology used by Enable Injections is especially well suited for administering sensitive drugs, such as painkillers. Enable Injections is a private, venture-backed company. 2010 Year Founded, Status Private, 193 Employees, Latest Deal Type Series C, Latest Deal Amount $215M, Investors 14 https://pitchbook.com/profiles/company/55056-43. Cincinnati, OH.
8. Micropoint Technologies: American startup Micropoint Technologies creates and produces needle-free injection devices based on microneedles. Their devices pierce the skin with tiny needles that deliver medication straight to the cells. The technology offered by Micropoint Technologies is especially well-suited for the delivery of large-molecule medications, including DNA-based therapeutics and proteins. Symbol: Taiwan Stock Exchange (TWO).
9. Zosano Pharma: American business Zosano Pharma creates and produces needle-free injection equipment for biologic delivery. Their devices use a proprietary technology that uses a high-pressure liquid stream to deliver medication through the skin. Large-volume biologic delivery is a particularly good fit for the technology from Zosano Pharma. Company filed for bankruptcy in 2022. Its stock is now traded over-the-counter under the symbol ZSANQ. California-based Zosano threw in the towel over the summer in 2022, submitting the paperwork for Chapter 11 bankruptcy after back-to-back rejections by the FDA left it without the cash to mount a third push for approval of its transdermal migraine candidate. https://www.annualreports.com/HostedData/AnnualReports/PDF/NASDAQ_ZSAN_2021.pdf.
10. Nemaura Medical: An Israeli business called Nemaura Medical creates and produces needle-free injection equipment for the administration of medications and vaccines. Their devices use a special kind of microneedle technology that dissolves the tiny needles used to inject medicine into the skin. The technology offered by Nemaura Medical is especially well-suited for the delivery of sensitive drugs, such as painkillers. Symbol: NMRD https://finance.yahoo.com/quote/NMRD. Market Cap (intraday) 8,070. Loughborough, United Kingdom.
Internet Assessment of Needleless Injection
Jet injectors were used for mass vaccination, and as an alternative to needle
syringes for diabetics to inject insulin. However, the World Health Organization
no longer recommends jet injectors for vaccination due to risks of disease
transmission.
There is no needle-free insulin currently available; instead, you can get
a needle-free insulin delivery device like the VetPen or the Petfine
auto-injector, which attach to conventional syringes to make injections easier
and more comfortable for your pet. You can purchase these devices and the
necessary U-40 insulin from online pet supply retailers such as ADW Diabetes
and Amazon, or at a local Walmart for certain types of insulin. You will
need a veterinarian to prescribe the correct type of insulin and to determine
if an insulin pen or auto-injector is appropriate for your dog.
Disadvantages of needle-free injection include higher cost, potential for
bruising and dermal trauma like epidermal cysts, risk of infection due to
drug "splashback," device malfunctions such as clogging, difficulty with
precise dosage delivery, potential damage to drug molecules from high pressure,
and the risk of "wet" injections where the fluid doesn't fully penetrate
the skin.
The use of traditional jet injectors by the U.S. military ceased in the 1990s.
Today's jet injectors are single-use devices. Though they are not approved
by the Food and Drug Administration to deliver a coronavirus vaccine, they
do deliver flu vaccines.
The military embraced the needle-free technique of delivering vaccines. Concerns
about passing along bloodborne pathogens curtailed the use of multi-use injectors
in the 1990s.
Jet injectors are not widely used for mass immunization due to the high risk
of transmitting bloodborne pathogens like hepatitis B and HIV through
contaminated equipment, which led to their discontinuation by the U.S. military
and a recommendation against their general use by the World Health Organization.
Other drawbacks included inconsistent vaccine delivery, increased pain and
flinching, and potential damage to the nozzle from splashback, making traditional
needle and syringe injections safer and more reliable.
Needle-free systems were the first described by marshalllockhart in 1936
in his patent jet injection. Then in the early 1940's higson and others developed
high pressure “guns”using a fine jet of liquid to pierce the skin
and deposit the drug in underlying tissue.
The insulin jet injector itself can cost anywhere from $200 to $700 in the
United States.
The vaccine given with a "gun" in the 1960s was the smallpox vaccine,
administered using a jet injector, a needle-less, gun-like device. These
"peace guns" used high-pressure, rapid expulsion to deliver the vaccine into
the skin, allowing for rapid mass vaccination during the global smallpox
eradication campaign.
Jet injectors, or needle-free injectors, are generally considered less painful than traditional needle-and-syringe injections because they deliver medication using a high-pressure stream of liquid instead of a sharp needle, eliminating the puncture pain. However, some people may feel pressure, a snap, or mild soreness at the injection site, and experiences vary individually.
Stakeholder Needs and Advantages
Over 650 thousand children in the world are diagnosed with juvenile diabetes.
Young families need improved access to safer, less painful, economically
viable, and more sustainable alternatives than hypodermic needles.
Provides faster absorption of medicine than hypodermic needles. Medication
is distributed over a larger area as opposed to needles that concentrate
the medication.
Reduces Fear. Patients report less pain and discomfort with needle-free
injections, making them more likely to adhere to medications. Meanwhile 20
percent of the global population has some degree of fear of needles or injections
and 10 percent within that number suffer from what is known as Trypanophobia.
This is an excessive or irrational fear of injections or needles which can
be learned or inherited. Many with Trypanophobia avoid getting medical treatment
that involves the use of needles, which can prove dangerous for those with
chronic medical conditions such as diabetes.
Eliminates needlestick injuries (NSI's), cross contamination and infections.
NSIs affect ~2.2% of HCW's in the US and Canada resulting in ~600,000 to
800,000 needlestick injuries reported annually. Needlestick injuries (NSIs)
are one of the most common health hazards facing healthcare workers (HCWs)
across the globe. Needles with safety engineered devices (SEDs) have been
developed to minimize the risk of exposure to blood-borne infections, such
as hepatitis B virus, hepatitis C virus and human immunodeficiency virus,
associated with NSIs. Despite the introduction of SEDs, the incidence of
NSIs increased from 1.9 per 100 HCWs before the introduction of SEDs to 2.2
per 100 HCWs after the introduction of SEDs.
Reduces Cost for both patients and Health Care System. Estimated cost of
Health Care Work (HCW) needlestick injury ranges between $500 and $4,000
USD per incident, not accounting long-term treatment costs associated with
illness contracted from the injury or litigation and compensation costs.
Between 600,000 to 800,000 needlestick injuries occur each year in the United
States. New staff or those unfamiliar with using needles or other percutaneous
equipment, have more needlestick injuries than experienced workers. Health
Canada notes that 41% of injuries occur during use, while 45% occur
post-use.
Sustainable Alternative to Reduce Biohazard Waste. Approximately 16 billion
disposable and non-recyclable injections are administered worldwide. In the
US, the estimated cost of a single Needlestick Injury (NSI) treatment ranges
between US$500 to US$4,000. For the more serious cases, however, the costs
can far exceed the average. According to the American Hospital Association,
one case of serious infection by bloodborne pathogens can cost US$1 million
or more in expenditures for testing, follow-up tests, lost time and disability
payments. Despite being staggeringly high, these costs are underestimated
in that they do not account for long-term treatment costs associated with
illness contracted from the injury or litigation and compensation costs.
Every year an estimated 16 billion injections are administered worldwide,
but not all of the needles and syringes are properly disposed of afterwards
nor are there recycling alternatives.
Diabetes is a major disease and is a leading cause of death in most countries. Approximately 1.5 million people worldwide died due to diabetes in 2019 and it is estimated that 463 million people are living with diabetes all over the world. Eighty percent live in low and middle income countries, and of the total, more than 60% live in Asia.
FDA - for USA
For human use in the USA, the U.S. Food and Drug Administration (FDA) does not issue "certifications" for mechanical devices. Instead, the agency regulates them through a classification system (Class I, II, or III) that determines the required premarket pathway, such as 510(k) clearance for most Class II devices or Premarket Approval (PMA) for high-risk Class III devices. Manufacturers must list their devices with the FDA and comply with general controls and specific controls or PMA requirements, depending on the device's risk class, to ensure safety and effectiveness for sale in the U.S.
Owners or operators of establishments that are involved in the production and distribution of medical devices intended for use in the U.S. are required to register annually with the FDA. This process is known as establishment registration (Title 21 CFR Part 807). Congress has authorized the FDA to collect an annual establishment registration fee for device establishments. A detailed list of the types of device establishments that are required to register and pay the fee can be found at “Who Must Register, List and Pay the Fee.” Generally, for FY 2025, there are no MDUFA Establishment Registration Fee waivers or reductions for small businesses. For FY 2026, the FDA may grant a waiver of the annual establishment registration fee (excluding the initial registration) to certain small businesses certified through the Small Business Determination (SBD) Program who demonstrate paying the fee represents financial hardship as determined by the FDA. The process is online and involves a fee for submission of the registration information.
Systems Assessment
This is a tough market as evidenced by the bankruptcies and slow growth. It is obvious that some serious marketing is needed to displace the existing status quo with massive entrenched business models. Needles as medical waste are an obvious problem that has not been properly addressed and should be part of all sustainability initiatives. The industry is probably focused on ease of use, safety, and patient fear of needles. This is a tough sell not unlike selling proper ventilation levels in public spaces. There has been venture capital funding but the results have been poor. With venture capital funding now going after the latest trend of AI startups, this industry is in a sink or swim mode. There will be consolidation with one large investor willing to take on the challenge of making needleless injectors ubiquitous. At this time it is unclear who will win in this space and change the world of injections.
There appear to be to two broad categories of needleless injection systems:
For mass injection systems, a protocol of sterilization and or disposable covers may allow these devices once again to be accepted especially, with mass human outbreaks. During COVID-19, these systems were rejected in favor of pre-filled disposable needles.
For personal use, especially for the delivery of insulin, there are significant advantages with using these systems. These systems have been approved for use in other countries. Mechanical devices in the USA are listed with the FDA.
The animal needs are different and both systems are equally viable. For animal use, there is no need for FDA approval. The personal use system allows individual animal owners to easily use the this approach. They offer many advantages over traditional disposable needles. The only possible issue is cost differences between constantly purchasing disposable needles and the one time purchase of a needleless injector.
CassBeth assumes no liability or responsibility for any of the investment or other information presented on its site.
Copyright © 1999 All Rights Reserved.